Investing in FemTech: From niche category to core healthcare infrastructure

Women’s health has long been an under-invested sector – with only a very limited number of large-scale platforms reaching unicorn status (including Flo Health’s 2024 fundraising).

We’ve discussed investment in FemTech and women’s health with both investors and senior executives at FemTech companies, looking at why it’s taken this long to have a FemTech unicorn and what FemTech companies have to do to make themselves investable. The good news for the sector in 2026 is that Q1 saw greater investment levels than the whole of 2025 combined – momentum that many will hope continues through the year.

For decades, medical research, clinical practice and healthcare investment were focused (probably unconsciously to a degree) around male physiology with largely male decision-makers. This didn’t stifle innovation, but it created a lack of awareness and understanding of, and willing to invest in, women-focused products and innovations.

Over the past decade, what initially emerged under the banner of “FemTech” – most visibly through fertility, pregnancy and cycle‑tracking applications – has matured into a broader women’s health innovation ecosystem. It spans diagnostics, therapeutics, regulated medical devices, AI‑enabled care pathways and integrated virtual‑care platforms.

With this broadening of the ecosystem, FemTech and women’s health platforms are becoming a more mainstream part of the healthcare landscape, bringing more investors to the table as they look to scale.

In this article, we explore how and why that shift has happened, where capital is flowing, which gaps are structurally underserved, and what funds should think about when allocating capital to women’s health businesses across equity and credit structures.

 

Why women’s health is now investable

With women making up just under 50% of the global population, the lack of investment in women’s health historically hasn’t been a question of demand. Instead, it’s suffered from more structural barriers.

For many years, women had significantly lower representation in investment committees. This meant key investment decisions were being made by people who struggled to intuitively relate to products addressing menstrual health, fertility, menopause or maternal mental health.

Those products were routinely categorised as “niche,” despite serving needs that affect roughly half the global population over the course of a lifetime. Compounding that perception problem was a genuine lack of rigorous clinical validation for many early solutions, alongside limited longitudinal data capable of demonstrating durable engagement, retention and outcomes.

What’s changed is meaningful on several fronts.

First, companies are running robust R&D. A new generation of women’s health companies has shown that software‑driven and data‑driven products can achieve regulatory‑grade clinical validation. When digital women’s health solutions began to secure clearances traditionally associated with medical devices alongside appealing data cases, the investment case shifted decisively.

“As women’s health products have become more clinically robust, consumer behaviour has become less volatile. Better data, better representation in research and less stigma translate into stronger engagement and retention, which in turn supports more predictable revenues.” Emma Jones, Senior Investment Analyst, Claret Capital Partners

Second, the demand is now undeniable. Large‑scale platforms addressing women’s health have demonstrated sustained engagement, strong retention and increasing willingness to pay across multiple life stages. Visibility of these metrics, rather than anecdotal discussions around the potential market size has opened investors’ eyes.

“The biggest change I’ve seen is societal. Women now have more influence, more visibility and more power to demand solutions that address their health properly. That shift is driving both research focus and adoption in women’s health.” Lisa Falco, Co-founder & CEO, M23 Health

Third, the founder and investor ecosystem has evolved. In addition to greater female representation at investor committee level, a growing cohort of successful women’s health founders have reinvested capital, experience and credibility back into the sector as angels, advisors and repeat founders. Recycling that expertise has helped professionalise execution and accelerate learning curves across the ecosystem.

Together, these developments have reframed women’s health from a perceived “category risk” into a credible healthcare opportunity grounded in data, evidence and scale.

“What changed is not the size of the market – that was always there – but the evidence. Stronger data, clearer regulatory pathways and proven scale have made women’s health a much more credible investment category.” Ben Marrel, CEO & Cofounder, Breega

 

From FemTech to mainstream healthcare

As the sector matures, the relevance of the term “FemTech” itself is being questioned. Women’s health innovation is increasingly thought of more as a core part of the healthcare ecosystem rather than as an ancillary sector. The strongest businesses in the space rarely present themselves as niche “female‑only” products, but rather as healthcare platforms designed to accommodate female biology as part of a holistic offering.

When women’s health is framed as niche, it risks being evaluated through a consumer‑app lens that undervalues clinical complexity, regulatory progression and long‑term data advantages. When it’s framed as healthcare infrastructure, it can be assessed using the same criteria as those applied to other scaled health platforms: quality of outcomes, regulatory robustness, defensible data moats and integration across care pathways.

“What really changed the investment conversation was regulatory‑grade clinical validation. When software‑driven women’s health products began to be approved as regulated medical devices, the thesis shifted from wellness or lifestyle to credible healthcare infrastructure.” Christian Leybold, Managing Partner, Headline

That said, the FemTech label has played – and continues to play – an important role in surfacing historic gaps in research and investment. Its enduring value may lie less in defining the category, and more in highlighting where persistent underinvestment and misdiagnosis are embedded in healthcare systems.

 

Where capital is flowing – and where gaps remain

Capital allocation in women’s health reflects a combination of patient need, commercial clarity and payer alignment.

Fertility and reproductive health attracts the largest share of investment. These sectors benefit from a high willingness to pay, well‑established clinical pathways and, in some jurisdictions, employer‑ or insurer‑supported reimbursement structures. From an investor perspective, they offer a relatively clear line of sight between demand, monetisation and clinical value.

Beyond fertility, momentum is building across menopause and perimenopause care, pelvic health, endometriosis, PCOS, diagnostics and AI‑enabled platforms that integrate symptom tracking, triage and treatment pathways. Large‑scale women’s health platforms increasingly function as longitudinal health companions, supporting users through multiple life stages rather than targeting single conditions.

Despite this progress, there are still material gaps. Areas such as maternal mental health, autoimmune disease and certain gynaecological conditions demonstrate clear clinical need but continue to face structural challenges. Fragmented payer landscapes, fear of stigma resulting from discussing conditions and seeking help, and complex reimbursement pathways can make even clinically compelling solutions difficult to scale.

A recurring theme across the investor community is that the deepest unmet needs in women’s health often sit at the intersection of research, regulation and system‑level adoption. These problems are solvable, but they frequently require longer development timelines and a more patient-capital mindset than traditional venture models were designed to accommodate. The question of how potential tools can be made to work for investors and bring in revenue is a critical issue.

 

Capital structures and sector maturity

As women’s health businesses scale, their financing profiles are becoming more sophisticated and more varied.

Angel investment and venture capital remain central in the early stages, particularly where companies are establishing clinical validation, building data sets and refining their go‑to‑market strategies. However, once engagement stabilises and revenue becomes more predictable, alternative capital structures are increasingly relevant.

From a credit perspective, women’s health companies are now often underwritten as healthcare businesses rather than consumer platforms. Venture debt typically becomes realistic once product‑market fit and unit economics are demonstrable, often at the later Series B or Series C stage. In women’s health, as elsewhere, capital ultimately follows scale: where there are paying customers, repeat usage and defensible economics, investment remains available. Investors are more likely to be interested once recurring revenues can be shown.

In that context, reduced stigma, improved clinical evidence and better data quality, which have translated into more durable user behaviour, are often a critical prerequisite for lendability, and something which venture capital investors will look for.

Strategic partnerships have also become an increasingly important part of the financing architecture. Collaborations with hospital networks, insurers, pharmaceutical companies and employer benefits platforms can be important to establishing credibility, particularly to financial investors in demonstrating more assured revenue streams. They also help provide non‑dilutive capital, accelerating distribution and, in many cases, laying the groundwork for an eventual exit.

“If you want to build a sustainable health business, you need to align with the healthcare system. Working with insurers creates a very different dynamic from purely direct‑to‑consumer models, both in terms of stability and scale.” Dr Valerie Kirchberger, M.D., Founder & Co-CEO, Evela Health

 

Founders, lived experience and execution discipline

Women’s health stands out in the tech-enabled healthcare sectors for the prominence of female founders and leadership teams. Lived experience can play a decisive role in identifying meaningful problems and designing products that users trust and engage with over time.

That proximity to the problem can be a commercial advantage. In areas where sustained behavioural engagement is essential – such as fertility management or chronic condition support – products designed with both empathy for the user and credibility can outperform technically comparable alternatives. Trust in how data will be handled in such a sensitive area is critical to user confidence.

However, experienced investors are clear that lived experience alone isn’t sufficient. Successful women’s health companies are those that combine mission with execution discipline: rigorous clinical validation, regulatory awareness, clarity on who pays and why, and a credible pathway to scale.

“Impact alone isn’t enough. If you want to create lasting impact in women’s health, you need a clear business case and a willingness to pay that works in practice. Without that, you won’t survive long enough to make a difference.” Lisa Falco, Co-Founder & CEO, N23 Health

 

Exit dynamics and long‑term value creation

Exit activity in women’s health has historically been driven by strategic acquisitions rather than public listings. Acquirers tend to prioritise platforms over point solutions, valuing scale, regulatory robustness and trusted data over short‑term growth metrics.

As the sector matures, exit readiness is increasingly defined by governance standards, data stewardship and integration into broader healthcare value chains. Businesses that defer these considerations may achieve early growth but struggle to translate that momentum into durable exit outcomes or successful scaling.

While large‑scale IPOs in women’s health are still relatively rare, many investors see a credible pathway emerging for global platforms that combine scale, regulatory compliance and long‑term engagement. In that context, women’s health is increasingly viewed not as a specialist category, but as a long‑term infrastructure play capable of sustaining public market scrutiny.

 

Political, regulatory and LP considerations

Women’s health doesn’t exist in a political or regulatory vacuum. Sensitivities around reproductive health and personal data vary significantly by jurisdiction and can influence both consumer perception and institutional investor discussions.

In practice, most investors view these risks as manageable rather than prohibitive. Robust governance, thoughtful disclosures and careful jurisdictional structuring are increasingly standard tools for managing regulatory exposure and LP concerns. While scrutiny has undoubtedly increased, it hasn’t materially dampened appetite for high quality women’s health assets with credible fundamentals.

 

Conclusion

Women’s health is no longer an experimental or peripheral investment theme. It’s increasingly recognised as core to healthcare innovation, underpinned by clinical maturity, demographic demand and evolving capital structures.

For funds, the question is no longer whether women’s health deserves investment, but how capital can be deployed responsibly, patiently and profitably to close some of healthcare’s most persistent gaps.

The key message for founders is clear: to be investable, women’s health and FemTech businesses must combine strong products with robust data, clear revenue visibility and credible pathway to scale.

With thanks to the following people for their input into this article:

• Lisa Falco, Co-Founder & CEO, N23 Health
• Emma Jones, Senior Investment Analyst, Claret Capital Partners
• Dr Valerie Kirchberger, M.D., Founder & Co-CEO, Evela Health
• Christian Leybold, Managing Partner, Headline
• Ben Marrel, CEO & Cofounder, Breega
• Yannick Oswald, Partner, Mangrove Capital Partners

This article is part of the FemTech Now series. Access the hub here